Showing results (81-90 of 97) with videos related to
Sort By:
Pageof 10
Diabetes & Metabolism Journal|June 20, 2022
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing SurveillanceJun Sung Moon, Nam Hoon Kim, Jin Oh Na, et al.Diabetes & Metabolism Journal|June 26, 2018
Corrigendum: Hemorheologic Alterations in Patients with Type 2 Diabetes Mellitus Presented with an Acute Myocardial InfarctionKyu Hwan Park, Ung Kim, Kang Un Choi, et al.Diabetes & Metabolism Journal|April 21, 2018
Hemorheologic Alterations in Patients with Type 2 Diabetes Mellitus Presented with an Acute Myocardial InfarctionKyu Hwan Park, Ung Kim, Kang Un Choi, et al.Diabetes|January 30, 2007
Glucotoxicity in the INS-1 rat insulinoma cell line is mediated by the orphan nuclear receptor small heterodimer partnerKeun-Gyu Park, Kyeong-Min Lee, Hye-Young Seo, et al.Journal of Korean Medical Science|June 4, 2023
Medial Arterial Calcification and the Risk of Amputation of Diabetic Foot Ulcer in Patients With Diabetic Kidney DiseaseJoon Myeong So, Ji Ho Park, Jin Gyeong Kim, et al.Diabetes & Metabolism Journal|July 9, 2011
A survey of diabetic educators and patients for the revision of korean food exchange listsJae Won Cho, Mee Ra Kweon, Young Mi Park, et al.Diabetes, Obesity & Metabolism|March 5, 2023
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trialSoo Heon Kwak, Kyung Ah Han, Kyung-Soo Kim, et al.Diabetes, Obesity & Metabolism|April 5, 2023
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trialYe Seul Yang, Kyung Wan Min, Seok-O Park, et al.Journal of Diabetes|May 9, 2015
Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trialSang-Man Jin, Jae Hyeon Kim, Kyung Wan Min, et al.Diabetes & Metabolism Journal|September 26, 2023
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week ExtensionJun Sung Moon, Il Rae Park, Hae Jin Kim, et al.Pageof 10